Study Summary
This trial is testing a new drug for people with leukemia who haven't responded to other treatments. The drug will be given in increasing doses to see what effect it has.
- Acute Myeloid Leukemia
- Acute Lymphoblastic Leukemia
- Mixed Phenotype Acute Leukemia
Treatment Effectiveness
Effectiveness Progress
Study Objectives
2 Primary · 10 Secondary · Reporting Duration: Day 1 and Day 23 of Cycle 1 (each cycle is 28 days)
Trial Safety
Safety Progress
Trial Design
6 Treatment Groups
Dose Escalation - Level 4
1 of 6
Expansion Arm at RP2D
1 of 6
Dose Escalation - Level 5
1 of 6
Dose Escalation - Level 1
1 of 6
Dose Escalation - Level 3
1 of 6
Dose Escalation - Level 2
1 of 6
Experimental Treatment
50 Total Participants · 6 Treatment Groups
Primary Treatment: MRX-2843 · No Placebo Group · Phase 1
Trial Logistics
Trial Timeline
Who is running the clinical trial?
Eligibility Criteria
Age Any Age · All Participants · 9 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:Frequently Asked Questions
Is the enrollment window for this study still open?
"This clinical trial is actively recruiting participants, as indicated by its listing on the clinicaltrials.gov site. The posting date of April 1st 2022 and most recent update from July 6th are also noted there." - Anonymous Online Contributor
Has the FDA given its blessing for MRX-2843 to be utilized in medical treatments?
"MRX-2843 received the lowest safety rating, 1 out of 3, as this is a Phase 1 trial. This indicates that there is only minimal data so far in terms of efficacy and safety." - Anonymous Online Contributor
What is the ceiling of participants for this research endeavor?
"Affirmative. The information on clinicaltrials.gov suggests that this medical trial is actively recruiting patients - it was initially posted on April 1st 2022 and last updated on July 6th 2022. Approximately 50 individuals must be sourced from 3 distinct sites for the study to reach completion." - Anonymous Online Contributor